Brecanavir

From Self-sufficiency
Jump to: navigation, search
Brecanavir
File:Brecanavir.png
Systematic (IUPAC) name
[(3R,3aS,6aR)-2,3,3a,4,5,6a-Hexahydrofuro[5,4-b]furan-3-yl] N-[(2S,3R)-4-(1,3-benzodioxol-5-ylsulfonyl-(2-methylpropyl)amino)-3-hydroxy-1-[4-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl]butan-2-yl]carbamate
Identifiers
CAS Number 313682-08-5
ATC code none
PubChem CID 5743186
Chemical data
Formula C33H41N3O10S2
Molar mass 703.82[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Brecanavir (INN; codenamed GW640385) is a protease inhibitor which has been studied for the treatment of HIV.[1]

On December 2006, its developer, GlaxoSmithKline discontinued further development because of insurmountable issues regarding formulation.[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  2. "GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385)" (Press release). GlaxoSmithKline. 2006-12-18. http://www.gsk.com/media/pressreleases/2006/2006_12_18_GSK945.htm. Retrieved 2008-06-11.